DUBLIN, Ohio and PRINCETON, N.J., Sept. 8 /PRNewswire/ -- Neoprobe Corporation , a diversified developer of innovative oncology surgical and diagnostic products and Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that they have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under this agreement, Laureate will assist in the development and production of Neoprobe's murine monoclonal antibody CC49 called RIGScan((R)) CR, a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.
"We are delighted that Neoprobe has selected Laureate Pharma as their development and manufacturing partner," said Robert J. Broeze, Ph. D., President & Chief Executive Officer of Laureate Pharma. "We will work closely in partnership with the Neoprobe biotech team and assist them in driving their product from development into the clinic."
About Laureate Pharma
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGOLaureate Pharma
